Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ziying Granules
- Development stage
- Phase 2
- Lead developer
- Fangsheng Pharmaceutical
- Administration
- Oral
01
Overview
Ziying Granules (紫英颗粒) is an investigational Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical for the treatment of gynecological conditions, specifically chronic pelvic inflammatory disease (CPID) and its sequelae. The drug is formulated as oral granules and is designed to alleviate symptoms such as chronic pelvic pain and inflammation associated with pelvic inflammatory disease. It has been evaluated in Phase 3 clinical trials in China, positioning it as a late-stage candidate in the developer's gynecological pipeline. As a TCM product, it likely utilizes a multi-component approach to address the complex pathophysiology of chronic inflammation in the female reproductive system.
- Other names
- 紫英颗粒Ziying Keli
Beyond the preview
Go deeper on Ziying Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ziying Granules.